Anton Neschadim work email
- Valid
- Valid
- Valid
- Valid
Anton Neschadim personal email
- Valid
I am a biomedical industry executive, scientist, innovator, entrepreneur and venture capitalist with more than 20 years of combined industry and academic experience in research, drug development and venture capital. My experience and education bridges business administration and biomedical research, and enabled me to effectively lead and manage therapeutic drug development and R&D efforts in the biotechnology industry. My venture capital investment experience spans deal sourcing, evaluation and due diligence of seed to series A investment opportunities across biotech, health tech and deep tech sectors.With an infinite passion for the transformative benefits of biomedical research and biotechnology to our society, I am an integrative thinker employing my multi-disciplinary experience to advance the development of therapeutics that can address significant unmet clinical need.I am known for developing novel biological therapeutics and gene therapy treatment modalities, and published scientific works and patents across all major areas of biomedical research, including immunology, oncology, regenerative medicine, gene therapy and biological chemistry.Specialties: Biomedical Research, Drug Development, Biotechnology Consulting, Venture Capital, Board Management, Non-for-Profit Experience
-
CeoImmunobiochem CorporationToronto, On, Ca
-
Venture Capital, Senior AdvisorGreensky Ventures 2016 - PresentToronto, Ontario, CaGreenSky Ventures, investing from its GreenSky Accelerator Funds, is a venture capital fund focused on making Seed and Series A round investments in high-growth, early-stage opportunities. Rebranded from GreenSky Capital Inc., the GreenSky Accelerator Funds have access to a robust network of deal flow and takes an institutional approach to early-stage investing.Anton joined GreenSky Capital as a Venture Capital Associate in 2016 and is currently a Senior Advisor at GreenSky Ventures. -
CeoImmunobiochem Corporation 2015 - PresentToronto, Ontario, CaImmunoBiochem is developing novel tumor microenvironment-targeted potentiated biologics for oncology, designed to overcome the challenges associated with tumor heterogeneity that limit the impact of targeted therapeutics. ImmunoBiochem's internalizing antibody-drug conjugates (ADCs) are based on fully-human antibodies developed using state-of-the-art phage display technologies. ImmunoBiochem's ADCs are in development for Triple-Negative Breast Cancer - an aggressive indication for which no targeted biologics are currently available.
-
DirectorImmunobiochem Corporation 2007 - PresentToronto, Ontario, CaImmunoBiochem is developing novel tumor microenvironment-targeted potentiated biologics for oncology, designed to overcome the challenges associated with tumor heterogeneity that limit the impact of targeted therapeutics. ImmunoBiochem's internalizing antibody-drug conjugates (ADCs) are based on fully-human antibodies developed using state-of-the-art phage display technologies. ImmunoBiochem's ADCs are in development for Triple-Negative Breast Cancer - an aggressive indication for which no targeted biologics are currently available.
-
Chief ExecutiveNanovista Inc. 2020 - PresentNanovista, based at JLABS@Toronto, is developing novel mutli-modality imaging agent for surgical oncology to enable intraoperative visualization of solid tumors and tumor margins. -
Director, Drug DevelopmentArmour Therapeutics Inc. 2010 - 2015Armour Therapeutics is a biopharmaceutical company focused on the development of a new class of anti-hormone therapeutics for the treatment of reproductive tissue-based cancers. Armour’s compounds are designed to maintain an anti-androgen effect in patients developing resistance to currently marketed anti-hormonals, with the additional benefit of blocking the relaxin hormone pathway, which in turn reduces tumour growth, impairs angiogenesis, constricts tumoral blood flow and reduces the risk for metastasis. Armour's anti-hormone therapy synergistically combines with certain marketed chemotherapeutics for increased efficacy and is being developed as both a monotherapy as well as a combination therapy for mid-stage to end-stage prostate cancer. Armour’s lead compound, AT-001, developed at the University Health Network and Ontario Cancer Institute in Toronto, is a relaxin receptor antagonist for patients who develop hormone-refractory prostate cancer. Armour is also developing compounds for its AT-012 and AT-027 programs targeting breast and ovarian cancers, respectively.
-
Organizing Committee, Revenue Development Sub-Committee Co-ChairCanadian Science Policy Conference Sep 2008 - 2013The Canadian Science Policy Conference (CSPC) was founded in 2009 by a diverse group of young and passionate professionals from industry, academia, and science-based governmental departments. CSPC serves as an inclusive, non-partisan and national forum uniting stakeholders, strengthening dialogue, and enabling action with respect to current and emerging issues in national science, technology, and innovation policy. The CPSC is a grassroots initiative that thrives on a dynamic and responsive conference structure focused on best serving the needs of the science policy community.
-
Founding Member Of The Board Of DirectorsCanadian Science Policy Centre Nov 2009 - Jan 2012Richmond Hill, Ontario, CaThe Canadian Science Policy Conference (CSPC) was founded in 2009 by a diverse group of young and passionate professionals from industry, academia, and science-based governmental departments. CSPC serves as an inclusive, non-partisan and national forum uniting stakeholders, strengthening dialogue, and enabling action with respect to current and emerging issues in national science, technology, and innovation policy. The CPSC is a grassroots initiative that thrives on a dynamic and responsive conference structure focused on best serving the needs of the science policy community. -
ResearchUniversity Health Network 2005 - 2011Toronto, Ontario, Ca -
ReseachSunnybrook Health Sciences Centre 2002 - 2004Toronto, Ontario, Ca
Anton Neschadim Skills
Anton Neschadim Education Details
-
Harvard Business School Executive EducationMergers & Acquisitions -
Mit Sloan Executive EducationInterpersonal Communication Strategies For Executives
-
Stanford University Graduate School Of BusinessExecutive Program In Leadership
-
Yale School Of ManagementNegotiation Strategies
-
Harvard Business School Executive EducationValue Measurement For Health Care
-
University Of Toronto - Rotman School Of ManagementEvening Part-Time
-
University Of TorontoDepartment Of Medical Biophysics - Gene Therapy
-
University Of TorontoDepartment Of Immunology
-
University Of Toronto - University CollegeBiological Chemistry Specialist
Frequently Asked Questions about Anton Neschadim
What company does Anton Neschadim work for?
Anton Neschadim works for Immunobiochem Corporation
What is Anton Neschadim's role at the current company?
Anton Neschadim's current role is CEO.
What is Anton Neschadim's email address?
Anton Neschadim's email address is co****@****hem.com
What schools did Anton Neschadim attend?
Anton Neschadim attended Harvard Business School Executive Education, Mit Sloan Executive Education, Stanford University Graduate School Of Business, Yale School Of Management, Harvard Business School Executive Education, University Of Toronto - Rotman School Of Management, University Of Toronto, University Of Toronto, University Of Toronto - University College.
What are some of Anton Neschadim's interests?
Anton Neschadim has interest in Science Policy, Information Technology, Research, Biotechnology, Investments, Immunology, Gene Therapy.
What skills is Anton Neschadim known for?
Anton Neschadim has skills like Biotechnology, Molecular Biology, Immunology, Biochemistry, Drug Development, Research, Life Sciences, Cell, Clinical Research, Data Analysis, Science, Oncology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial